Related Experiment Video
Updated: Aug 29, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
Cardiomyopathy in congenital disorders of glycosylation
Josef Gehrmann1, Kristina Sohlbach, Michael Linnebank
1Department of Pediatric Cardiology, Westfalische Wilhelms-Universitat Munster/Westf., Munster, Germany.
Insights
Congenital disorders of glycosylation (CDG) can cause serious heart problems, including cardiomyopathy. Early screening for cardiac issues in children with CDG is crucial for managing this multisystem disorder and improving outcomes.
Area of Science:
- Cardiology
- Genetics
- Metabolic Disorders
Background:
- Congenital disorders of glycosylation (CDG) are inherited metabolic diseases affecting protein and lipid glycosylation.
- Neuromuscular disease is a common feature, but cardiac involvement is increasingly recognized.
Purpose of the Study:
- To investigate the cardiological manifestations in patients with congenital disorders of glycosylation.
- To assess the prevalence and characteristics of cardiomyopathy in CDG.
Main Methods:
- Literature review of six pediatric cases with CDG and cardiac disease.
- Cardiovascular screening of 20 patients diagnosed with CDG at the authors' institution.
Main Results:
- In the literature cohort, hypertrophic cardiomyopathy was identified in 4 of 6 patients.
- In the authors' cohort, 15% of patients had coexistent cardiomyopathy (dilated in two-thirds, hypertrophic in one-third).
- Cardiac involvement significantly contributed to morbidity and mortality, including sudden cardiac death.
Conclusions:
- Congenital disorders of glycosylation should be considered in the differential diagnosis of pediatric cardiomyopathy.
- Routine cardiac screening is recommended for all patients diagnosed with CDG to detect associated cardiomyopathy.
Abstract:
Congenital disorders of glycosylation are a group of inherited metabolic multisystem disorders characterized by defects in the glycosylation of proteins and lipids. In most cases, neuromuscular disease is present. The purpose of this study was to characterize the cardiological aspects in this disorder. From the literature, we identified six children with congenital disorders of glycosylation associated with cardiac disease. We then screened for cardiovascular manifestations 20 patients diagnosed with congenital disorders of glycosylation at our own institution. Of the 6 patients identified in the literature, 4 had hypertrophic cardiomyopathy, while in the other 2 the cardiac diagnosis was unclear. The mean age at cardiac diagnosis was 5 months, with a range from 34 weeks to 24 months. Of the patients, five had died at a mean age of 3.5 months, with a range from 1.5 to 6 months, with one documented cardiac death. Three of our 20 patients (15%) had coexistent cardiomyopathy, and in three additional patients presenting with cardiomyopathy we made the diagnosis of a congenital disorder of glycosylation. In our cohort, dilated cardiomyopathy was found in two-thirds of the patients, with hypertrophic cardiomyopathy in the other third. The mean age at cardiac diagnosis was 19 months, with a range from 0.5 to 84 months. Of these patients, two died in infancy at a mean age of 4 months, specifically at 1.5 and 7 months, due to cardiac disease, with one dying suddenly. The remaining four patients are alive with minor to severe cardiac dysfunction. We conclude that congenital disorders of glycosylation have to be considered in the differential diagnosis of children presenting with cardiomyopathy, and that all patients with congenital disorders of glycosylation should be screened for an associated cardiomyopathy. Cardiac involvement contributes significantly to morbidity and mortality, and probably to sudden cardiac death in this disorder.
Related Concept Videos
Inborn Errors of Metabolism
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Proteoglycans

